logo
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC

Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC

Korea Herald2 days ago

SINGAPORE, June 12, 2025 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global healthcare survey of its kind. The report draws insights on key concerns from healthcare professionals and patients in 16 countries, including Australia, Indonesia, and South Korea. Findings show that despite strong optimism about artificial intelligence's (AI) potential to ease pressure on APAC's healthcare systems, trust and implementation concerns persist.
"The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people."
Worsening patient outcomes because of care delays call for accelerated AI adoption
About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days.
Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times.
AI has the potential to transform care delivery and significantly improve patient outcomes across APAC.
Workforce challenge and data burdens call for AI relief
Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago.
These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden. [1]
About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented:
Addressing AI concerns from HCPs and patients crucial for widespread adoption
A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes.
Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%).
Trust key to transforming healthcare in APAC
For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area.
For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%).
Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies.
"It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems."
For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips.
About the Future Health Index 2025
The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit www.philips.com/futurehealthindex-2025.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Korea Herald

timea day ago

  • Korea Herald

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'
Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'

Korea Herald

timea day ago

  • Korea Herald

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'

SEOUL, South Korea, June 13, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 13th that it will participate in the 2025 BIO International Convention (BIO USA), which will be held in Boston, USA from June 16 to 19 (local time). At this year's BIO USA, Neurophet will introduce its software solution, Neurophet AQUA AD, which enables monitoring of prescription, treatment efficacy, and side effects of treatment for Alzheimer's disease. Neurophet AQUA AD provides precise brain imaging analysis throughout the course of anti-amyloid antibody therapy by quantitatively analyzing MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans. Lately, Alzheimer's disease clinical trials have been rising significantly in the biopharmaceutical industry which led to the importance of quantitative brain imaging biomarker analysis. Alzheimer's disease drugs such as Leqembi (lecanemab) and Kisunla (donanemab) require essential monitoring for potential side effects, which Neurophet AQUA AD can provide and meet demand for global expectations. Neurophet will exhibit at the Korea Pavilion, jointly organized by the Korea Biotechnology Industry Organization and the Korea Trade-Investment Promotion Agency (KOTRA), and showcase Neurophet AQUA AD along with its suite of neuroimaging and brain stimulation solutions. It includes Neurophet AQUA, a neurodegeneration imaging analysis software; Neurophet SCALE PET, a PET image quantification software; Neurophet tES LAB, a treatment planning software for brain stimulation; and Neurophet innk, a transcranial electrical stimulation (tES) device. Neurophet plans to strengthen its imaging CRO (Contract Research Organization) business for clinical trials related to Alzheimer's disease treatment through business meetings at this year's BIO USA. The company will also engage in partnering activities with global big pharma and potential clients. Jake Junkil Been, Co-CEO of Neurophet said that "Neurophet AQUA AD has garnered significant interest from both South Korea and global companies in the field of brain imaging-based biomarker development. Through our participation in BIO USA, we aim to accelerate business development collaborations in the imaging CRO sector and further expand into the companion diagnostics market." BIO USA is the world's largest biotechnology exhibition, serving as a global networking hub where stakeholders across the pharmaceutical and biotech industries come together to explore partnership opportunities. This year's event is expected to host over 1,500 companies and more than 20,000 participants from around the world. About Neurophet Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS". Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.

Osstem Implant, Exhibits cutting edge Digital Dentistry full lineup at the FAMDENT Show Mumbai 2025
Osstem Implant, Exhibits cutting edge Digital Dentistry full lineup at the FAMDENT Show Mumbai 2025

Korea Herald

timea day ago

  • Korea Herald

Osstem Implant, Exhibits cutting edge Digital Dentistry full lineup at the FAMDENT Show Mumbai 2025

SEOUL, South Korea, June 12, 2025 /PRNewswire/ -- Osstem Implant will participate in the FAMDENT Show Mumbai at the Bombay Exhibition Center in Mumbai, India, from June 20 to 22 next month. At this exhibition, Osstem will hold a special promotion along with a booth exhibition for various digital dentistry lineups. The FAMDENT Show Mumbai is one of the most popular dental exhibitions in India, where dental brands and suppliers showcase and demonstrate new products every June. You can check out the latest trends in the global dental industry, and it has established itself as a platform for dentists and dental industry officials to purchase excellent dental products. Participants of the exhibition are given 18 points of continuing dental education (CDE) certified by the Maharashtra State Dental Council (MSDC), which attracts many Indian dentists every year. This year, more than 200 companies and 10,000 dentists and officials are expected to participate in this show. In this FAMDENT Show, Dr. Milind Karmarkar, the main performer, 20 other performers will play at the Scientific Conference. Among them, Dr. Vipin Mahurkar, a performer of Osstem, plans to give a lecture under the theme "Digital Dentistry – A revolution toads simplicity and acuity," which is expected to attract enthusiastic responses from participants interested in digital dentistry. Osstem will display CBCT T2 and MEDIT Oral Scanner, representative digital dentistry products, at the FAMDENT. CBCT T2 has significantly improved the resolution from 0.2mm Voxel to 0.8mm Voxel, and provides an image size (FOV: Field of View) of up to 15*15cm to diagnose not only the entire oral cavity but also specific areas such as maxillary sinuses and temporomandibular joints. This product is already very popular in the premium CBCT market. The MEDIT oral scanner "Medit i900," which will be introduced by Osstem at the exhibition, is intuitively easy to operate with the Touch Band and the Touch Pad, and the weight of the product is reduced to 165 grams, so it is designed to prevent wrist and shoulder strain even when used for a long time, increasing convenience. In addition, its own technology, "dual camera scan" algorithm, has been applied to maximize accuracy. Not only the oral scanner, but also the unit-chair K5 and the portable X-ray N1 will be displayed together. K5 and N1 are products that have won the top three global design competitions, and are receiving favorable reviews for their excellent performance and aesthetic appearance. Osstem offers special benefits to exhibitors at the exhibitions. Participants can buy Osstem products at a lower price when they purchase them at the exhibition site. They can also sign up for "Denall," an Ostem dental shopping mall, and receive A-Oss (bone graft material) or Hysil (impression material) products for free when they purchase the first product. Meanwhile, Osstem signed an exclusive sales and supply contract with Medit, a global oral scanner company, in May for Medit oral scanner products (excluding wireless products) in India. "We will strive to provide better value to customers based on partnerships with global companies with excellent product power," an official at Osstem India said. "We will strive to revitalize digital dentistry in the Indian dental market."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store